Pharvaris N.V.
PHVS | NASDAQ
$35.30
-$0.72 (-2.00%)
Sep 22, 2026, 2:03 PM ET · Market open
Company Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer |
| Anne Lesage | Chief Early Development Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Maryann Cimino | Director of Corporate Relations |
| Peng Lu | President |
| Stefan Abele | Chief Technology Operations Officer |
| Wim Souverijns | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4 | Filing |
| Aug 12, 2026 | 6-K | Filing |
| Jul 31, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 15, 2026 | 4 | Filing |
| Jul 14, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jun 29, 2026 | 4 | Filing |
Pharvaris N.V.
| Country | Switzerland |
| IPO Date | Feb 3, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 148 |
| CEO | Berndt Modig |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001830487 |
| CUSIP Number | n/a |
| ISIN Number | NL00150005Y4 |
| SIC Code | 2834 |
Recent News
- 6 days ago / defenseworld.netAnne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
- 6 days ago / defenseworld.netPharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC
- 7 days ago / seekingalpha.comPharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 7 days ago / zacks.comPHVS Stock Rises 10% in a Month: What Is Driving the Rally?
- 13 days ago / seekingalpha.comPharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
- 14 days ago / seekingalpha.comPharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
- 14 days ago / reuters.comPharvaris' genetic disorder drug meets main goal in late-stage trial
- 1 month ago / globenewswire.comPharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
- 2 months ago / globenewswire.comAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
- 2 months ago / zacks.comWall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
Add to Watchlist
Select watchlists to add or remove PHVS